District Court's Interpretation of Mayo in Ariosa Diagnostics Does Not Bode Well for Patent Eligibility of Diagnostics and Personalized Medicine

Abstract

Biotechnology Law ReportVol. 33, No. 2 The Holman ReportDistrict Court's Interpretation of Mayo in Ariosa Diagnostics Does Not Bode Well for Patent Eligibility of Diagnostics and Personalized MedicineChristopher M. HolmanChristopher M. HolmanSearch for more papers by this authorPublished Online:16 Apr 2014https://doi.org/10.1089/blr.2014.9990AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited bySocial Work and Genetics2 August 2019Congress Considering Legislation Intended to Reverse the Recent Trend Toward Devaluation of the U.S. Patent Right Christopher M. Holman9 October 2018 | Biotechnology Law Report, Vol. 37, No. 5Mayo Update: Some Reason for Guarded Optimism Christopher M. Holman1 October 2016 | Biotechnology Law Report, Vol. 35, No. 5Do Biotech Patent Lawsuits Really “Overwhelmingly Lose?”: A Response to Our Divided Patent System Christopher M. Holman21 April 2015 | Biotechnology Law Report, Vol. 34, No. 2Caught Between a Rock and a Hard Place: How Limelight Compounds the Challenges Facing Biotechnology Innovators After Mayo and Myriad Christopher M. Holman14 August 2014 | Biotechnology Law Report, Vol. 33, No. 4 Volume 33Issue 2Apr 2014 InformationCopyright 2014, Mary Ann Liebert, Inc.To cite this article:Christopher M. Holman.District Court's Interpretation of Mayo in Ariosa Diagnostics Does Not Bode Well for Patent Eligibility of Diagnostics and Personalized Medicine.Biotechnology Law Report.Apr 2014.46-48.http://doi.org/10.1089/blr.2014.9990Published in Volume: 33 Issue 2: April 16, 2014PDF download